{"id":"syhx1901","safety":{"commonSideEffects":[{"rate":null,"effect":"Common adverse event"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action of SYHX1901 is not well understood, but it is believed to work by interacting with the molecular target, leading to a specific therapeutic effect.","oneSentence":"SYHX1901 is a small molecule drug that targets the molecular target.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:36:56.913Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Indication 1"}]},"trialDetails":[{"nctId":"NCT06562894","phase":"PHASE2","title":"Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients","status":"NOT_YET_RECRUITING","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2025-05-26","conditions":"Severe Alopecia Areata","enrollment":156},{"nctId":"NCT06943950","phase":"PHASE3","title":"A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis","status":"NOT_YET_RECRUITING","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2025-06-01","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":500},{"nctId":"NCT06511739","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients","status":"RECRUITING","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2024-05-27","conditions":"Non-segmental Vitiligo","enrollment":144},{"nctId":"NCT05858047","phase":"PHASE2","title":"An Investigational Study to Evaluate Experimental Medication SYHX1901 Tablets With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2023-04-11","conditions":"Effects, Drug Side","enrollment":93},{"nctId":"NCT04880512","phase":"PHASE1","title":"The Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy Subjects","status":"UNKNOWN","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2021-05-31","conditions":"Healthy Subjects","enrollment":102}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SYHX1901","genericName":"SYHX1901","companyName":"CSPC Ouyi Pharmaceutical Co., Ltd.","companyId":"cspc-ouyi-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SYHX1901 is a small molecule drug that targets the molecular target. Used for Indication 1.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}